公开(公告)号：US20040146934A1

公开(公告)日：2004-07-29

申请号：US10350555

申请日：2003-01-23

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Office of Technology Transfer

Inventor： Claude F. Meares ,  Todd M. Corneillie

IPC: G01N033/53 ,  C07K016/46

CPC classification number: C07K16/44 ,  C07K16/1282 ,  C07K2317/31 ,  C07K2317/55 ,  G01N33/574

Abstract: The present invention provides a mutant antibody comprising a reactive site not present in the wild-type of the antibody and a antigen recognition domain that specifically binds to a metal chelate, wherein the reactive site is in a position proximate to or within the antigen recognition domain.

Abstract translation: 本发明提供了包含野生型抗体中不存在的反应性位点和与金属螯合物特异性结合的抗原识别结构域的突变体抗体，其中反应性位点处于接近或位于抗原识别结构域内的位置 。

公开(公告)号：US20040007877A1

公开(公告)日：2004-01-15

申请号：US10455755

申请日：2003-06-04

Applicant: California Institute of Technology ,  Office of Technology Transfer M/C 210-85, Cal Tech

Inventor： Justin Boland ,  Yu-Chong Tai

IPC: H02P009/04

CPC classification number: H02N1/08

Abstract: An apparatus for power generation. The apparatus has a first substrate comprising a conductive surface region and a second substrate coupled to the first substrate. Preferably, the second substrate comprises an electret material region, which is characterized by a substantially uniform electric field associated with the electret material region. The conductive substrate and the electret substrate are aligned in a significantly parallel fashion with a common area of each region directly facing the other region (A). A distance (d) characterizing a spatial separation is formed between the conductive surface region and the electret material region. A relative voltage potential (V) between the conductive substrate and the electret substrate is associated with the distance (d). In between the conductive substrate and the electret substrate is a material, liquid, gas, or combination with an associated permittivity (null0). The relative voltage potential changes based upon a change in the spatial separation between (d), a change in the overlapping area (A), or a change in the permittivity (null0) between the conductive surface region and the electret material region.

Abstract translation: 发电装置。 该装置具有包括导电表面区域的第一衬底和耦合到第一衬底的第二衬底。 优选地，第二衬底包括驻极体材料区域，其特征在于与驻极体材料区域相关联的基本均匀的电场。 导电基板和驻极体基板以与每个区域的直接面向另一区域（A）的公共区域显着平行的方式排列。 在导电表面区域和驻极体材料区域之间形成表征空间分离的距离（d）。 导电衬底和驻极体衬底之间的相对电压电位（V）与距离（d）相关联。 在导电基板和驻极体基板之间是具有相关介电常数（ε0）的材料，液体，气体或组合。 基于（d），重叠区域（A）的变化或导电表面区域和驻极体材料区域之间的介电常数（ε0）的变化的空间间隔的变化，相对电压电位发生变化。

公开(公告)号：US20020180446A1

公开(公告)日：2002-12-05

申请号：US10098996

申请日：2002-03-14

Applicant: The Regents of the University of California Office of Technology Transfer

Inventor： Werner Kuhr ,  David Bocian ,  Jonathan S. Lindsey ,  Kristian A. Roth

IPC: G01N027/416

CPC classification number: B82Y30/00 ,  B82Y10/00 ,  G01N27/3277

Abstract: This invention provides approaches to improve the signal to noise ratio (S/N) in electrochemical measurements (e.g. amperometry, voltammetry, etc.). In particular, a method is described wherein the faradaic current is temporally dissociated from the charging current associated with reading the charge of a redox-active species (e.g. a self-assembled monolayer (SAM)). This method, designated herein as open circuit potential amperometry (OCPA), quantitatively reads the charge of the redox species bound to (electrically coupled to) an electrode surface, while discriminating against both charging current(s) and amperometric signal(s) that arise, e.g. from diffusion-based species in solution.

Abstract translation: 本发明提供了改善电化学测量（例如电流分析法，伏安法等）中的信噪比（S / N）的方法。 特别地，描述了一种方法，其中法拉第电流与读取氧化还原活性物质（例如自组装单层（SAM））的电荷相关的充电电流暂时解离。 该方法在本文中指定为开路电位电流分析法（OCPA），定量地读取结合到（电耦合到）电极表面的氧化还原物质的电荷，同时区分出现的充电电流和电流测量信号 ，例如 从溶液中的基于扩散的物种。

公开(公告)号：US20020086428A1

公开(公告)日：2002-07-04

申请号：US09944715

申请日：2001-08-31

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Office of Technology transfer

Inventor： John Jelesko ,  Wilhelm Gruissem

IPC: C12N015/86 ,  C12N015/85

CPC classification number: C12N15/69 ,  C12N15/8216 ,  C12N15/85 ,  C12P19/34 ,  C12Q1/6844

Abstract: The invention provides methods and compositions for replicating a polynucleotide sequence independent of replication of chromosomal DNA in a cell.

Abstract translation: 本发明提供用于复制独立于细胞中染色体DNA复制的多核苷酸序列的方法和组合物。

公开(公告)号：US11766423B2

公开(公告)日：2023-09-26

申请号：US16977305

申请日：2019-03-01

Applicant: THE JOHNS HOPKINS UNIVERSITY ,  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH

Inventor： Barbara Slusher ,  Camilo Rojas ,  Ajit G. Thomas ,  Norman Haughey ,  Marc Ferrer ,  Xin Hu

IPC: A61K31/4178 ,  A61P25/28

CPC classification number: A61K31/4178 ,  A61P25/28

Abstract: Methods for treating one or more diseases associated with neutral sphingomyelinase 2 (nSMase2) in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically effective amount of 2,6-dimethoxy-4-(5-phenyl-4-thiophen-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) or a pharmaceutically acceptable salt thereof, are disclosed.

公开(公告)号：US11627907B2

公开(公告)日：2023-04-18

申请号：US16450895

申请日：2019-06-24

Applicant: Galiana Technology Inc. ,  National Institutes of Health, Office of Technology Transfer

Inventor： Bruce T Hope ,  Mark A Wells ,  Gregory D Sutton

IPC: A61B5/00 ,  A61B5/145 ,  A61B5/1473 ,  A61B5/07

Abstract: An intracellular monitoring device (IMD) that fits completely inside a living cell, and causes no significant impairment, to a cell's normal biological processes. The IMD monitors a cell for its level of a biological substance (e.g., calcium ion concentration) of interest. If the biological substance reaches or exceeds a threshold, the IMD transmits an electromagnetic signal, received by an antenna outside the cell. Each IMD has its electromagnetic signal encoded with a unique frequency. Detection of the frequency components, in the signals received by an antenna, permits identification of the source IMD's. A high calcium ion concentration is indicative of a strongly-activated cerebral cortex neuron. Brain tissue is relatively transparent to near infrared, making it a good frequency band, for the electromagnetic signals from neuron-monitoring IMD's. The near infrared of each IMD can be produced by quantum dots, powered by bioelectric catalysis triggered by high calcium ion concentration.

公开(公告)号：US20220409960A1

公开(公告)日：2022-12-29

申请号：US17623920

申请日：2020-06-30

Applicant: University of Florida Research Foundation, Inc. ,  THE REGENTS OF THE UNIVERSITY OF MICHIGAN OFFICE OF TECHNOLOGY TRANSFER

Inventor： Daniel Perry Ferris ,  Evangelia-Regkina Symeonidou ,  Steven Michael Peterson

IPC: A63B26/00 ,  A63B71/06 ,  A63B22/02 ,  A63B24/00

Abstract: Systems and methods are disclosed for human balance training. The systems and methods involve intermittently occluding the vision of a subject while the subject is engaged in a balance activity, such as walking on a balance beam, for example. Creating a brief period of continuous visual occlusion results in posterior parietal cortex activation, leading to enhanced balance training. The end result is much greater improvement in balance compared to physical training alone.

公开(公告)号：US20200323893A1

公开(公告)日：2020-10-15

申请号：US16754042

申请日：2018-10-08

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN OFFICE OF TECHNOLOGY TRANSFER

Inventor： Lonnie D. Shea ,  Robert S. Oakes ,  Grace Bushnell ,  Jacqueline S. Jeruss

IPC: A61K31/7068 ,  C12Q1/6886 ,  G16B25/10 ,  G16B40/30 ,  G16B40/20 ,  A61P35/04

Abstract: Provided herein are methods of determining a subject's metastatic potential, comprising measuring a level of expression of a gene, an RNA, or a protein, or a combination thereof, in a sample obtained from a synthetically-engineered pMN implanted in the subject, wherein the measured expression level of the gene, RNA, or protein in the sample is compared to a control level. Related methods are also provided herein.

公开(公告)号：US20200014247A1

公开(公告)日：2020-01-09

申请号：US16504192

申请日：2019-07-05

Applicant: The Regents of the University of Michigan, University of Michigan Office of Technology Transfer

Inventor： Al-Thaddeus Avestruz ,  Akshay Sarin

IPC: H02J50/12 ,  H02J50/80 ,  H02J7/02 ,  H02J50/40

Abstract: A device configured for wireless power transfer includes a digital controller configured to generate a plurality of switch control signals, and a transceiver configured to generate a wireless signal for the wireless power transfer. The transceiver includes a plurality of switches, each switch of the plurality of switches being responsive to a respective switch control signal of the plurality of switch control signals such that the wireless signal has a waveform shaped in accordance with a code sequence for the wireless power transfer. The code sequence is one of a set of predetermined code sequences, each predetermined code sequence being orthogonal to each other predetermined code sequence of the set of predetermined code sequences.

公开(公告)号：US10150802B2

公开(公告)日：2018-12-11

申请号：US15305831

申请日：2015-04-24

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ,  THE UNITED STATE OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH

Inventor： Christopher K. Garcia ,  Suman Mitra ,  Warren J. Leonard ,  Aaron M. Ring

IPC: C07K14/55 ,  A61K38/00

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2RP receptor and a decreased binding capacity for IL-2RΥc receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.